Since autophagy plays a dual role in the development of colorectal cancer, we should determine what role autophagy plays in each patient first and then establish a combination therapy, including CXCL8/CXCR1/CXCR2 antagonists and autophagy inhibitors/activators, to enhance the antitumor effects according to the CXCL8/CXCR1/CXCR2 and autophagy expression levels of the patient. This evidence concerns the gene CXCL8 and colorectal cancer.